Oragenics Inc
$ 0.55
0.16%
11 Aug - close price
- Market Cap 2,376,100 USD
- Current Price $ 0.55
- High / Low $ 0.55 / 0.51
- Stock P/E N/A
- Book Value 1.41
- EPS -1.42
- Next Earning Report 2026-08-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.06 %
- ROE -3.11 %
- 52 Week High 1.45
- 52 Week Low 0.48
About
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company is headquartered in Tampa, Florida.
Analyst Target Price
$2.00
Quarterly Earnings
| Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-08 | 2025-11-07 | 2025-08-08 | 2025-05-09 | 2025-03-14 | 2024-11-13 | 2024-08-09 | 2024-05-15 | 2024-03-29 | 2023-11-09 | 2023-08-14 | 2023-05-12 |
| Reported EPS | -0.51 | -1.96 | -3.1 | -3.65 | -0.2664 | -0.3773 | -0.509 | -0.701 | -4.1378 | -0.8543 | -1.5066 | -42.3 |
| Estimated EPS | None | 0 | 0 | None | None | None | None | None | None | None | -3 | -90.01 |
| Surprise | 0 | -1.96 | -3.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.4934 | 47.71 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | 49.78% | 53.0052% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-14 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OGEN
2026-07-31 15:11:14
This article provides a comprehensive stock analysis of Oragenics Inc (OGEN), highlighting its strong fundamentals and high growth potential despite recent weak stock market performance. The company's valuation is considered fair within the Biotechnology & Medical Research industry, and it benefits from very high institutional ownership and a favorable analyst rating. Oragenics Inc is a development-stage company focused on nasal delivery pharmaceutical medications for neurology and infectious diseases.
2026-07-29 05:43:07
This article provides a risk assessment for Oragenics Inc (OGEN), noting its current score of 2.55 and ranking 206 out of 385 in the Biotechnology & Medical Research industry. The company's beta value of 1.27 suggests high volatility relative to the S&P 500. The report details various metrics including maximum drawdown, volatility, return-to-drawdown ratio, skewness, and liquidity.
2026-07-29 03:39:41
The article discusses Oragenics Inc (OGEN)'s revenue breakdown, but states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. It primarily shows stock information and a placeholder for financial data that is currently unavailable.
2026-07-27 14:39:39
This article provides historical dividend and stock split information for Oragenics Inc (OGEN). It states that no dividends have been distributed in the past five years and lists several stock merger events, including a 30-to-1 merger in May 2025 and multiple 60-to-1 mergers in December 2022. The current stock price and market cap are also displayed.
2026-07-27 02:12:00
This article details the shareholder structure of Oragenics Inc (OGEN), listing major shareholders by proportion and type. It also provides institutional shareholding data across several quarters, including changes in the number of institutions and shares held. The report further highlights recent shareholder activity, showing changes in holdings by specific entities.
2026-07-26 07:42:11
This article provides the quarterly and annual cash flow statements for Oragenics Inc (OGEN), including operating, investing, and financing cash flows, with data extending back to FY2012Q1. It details changes in various cash flow components and offers FAQs explaining operating, investing, financing, and free cash flows. The financial data serves to evaluate the company's financial soundness and stability over time.
